Get the Stockscreener App
15.52
0.19%
0.03
After Hours:
15.52
Arcutis Biotherapeutics Inc stock is traded at $15.52, with a volume of 1.19M.
It is up +0.19% in the last 24 hours and up +3.54% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$15.49
Open:
$15.53
24h Volume:
1.19M
Relative Volume:
0.69
Market Cap:
$1.86B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.9592
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-2.91%
1M Performance:
+3.54%
6M Performance:
+21.25%
1Y Performance:
+41.09%
1-Day Range:
$15.10
$15.59
1-Week Range:
$15.10
$16.17
52-Week Range:
$8.03
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
15.52 | 1.86B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Will Arcutis Biotherapeutics Inc. continue its uptrendSwing Trade & Proven Capital Preservation Tips - Newser
Understanding Arcutis Biotherapeutics Inc.’s price movementMarket Movers & Fast Gain Swing Trade Alerts - Newser
Chart based analysis of Arcutis Biotherapeutics Inc. trendsLayoff News & Verified Momentum Stock Alerts - Newser
What high frequency data says about Arcutis Biotherapeutics Inc.Quarterly Profit Review & Target Return Focused Stock Picks - Newser
Is Arcutis Biotherapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Movers & Daily Stock Trend Reports - Newser
What momentum shifts mean for Arcutis Biotherapeutics Inc.2025 Year in Review & Verified Chart Pattern Signals - Newser
Can you recover from losses in Arcutis Biotherapeutics Inc.Weekly Risk Report & Consistent Profit Alerts - Newser
Is Arcutis Biotherapeutics Inc. still worth holding after the dipEarnings Growth Report & Real-Time Chart Breakout Alerts - Newser
Will Arcutis Biotherapeutics Inc. rebound enough to break even2025 Technical Patterns & Risk Controlled Swing Alerts - Newser
Tick level data insight on Arcutis Biotherapeutics Inc. volatility2025 Breakouts & Breakdowns & Verified Entry Point Detection - Newser
Using RSI to spot recovery in Arcutis Biotherapeutics Inc.2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - Newser
Arcutis Biotherapeutics Inc. stock retracement – recovery analysisWeekly Trade Review & Capital Efficient Trading Techniques - Newser
Published on: 2025-08-29 13:09:20 - Newser
Is Arcutis Biotherapeutics Inc. forming a bullish divergenceWeekly Trade Recap & Weekly High Momentum Picks - kpenews.com
Applying big data sentiment scoring on Arcutis Biotherapeutics Inc.Day Trade & Expert Approved Trade Ideas - Newser
Combining machine learning predictions for Arcutis Biotherapeutics Inc.Insider Selling & Low Risk High Win Rate Stock Picks - Newser
Quant Strategy Flags Arcutis Biotherapeutics Inc. for Entry getLinesFromResByArray error: size == 0 - thegnnews.com
What’s next for Arcutis Biotherapeutics Inc. stock pricePortfolio Update Summary & Capital Efficiency Focused Strategies - Newser
What technical models suggest about Arcutis Biotherapeutics Inc.’s comebackMarket Performance Recap & Community Consensus Stock Picks - Newser
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):